Defilade Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Defilade Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.3M	Buy	94,843 +42,948	+83%	+$10M	3.39%	12
2026 Q1	$11.9M	Sell	51,895 -33,799	-39%	-$7.58M	1.67%	26
2025 Q4	$18.3M	Buy	+85,694	New	+$17.7M	2.48%	18

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Defilade Capital Management's ASND Position: Q2 2026 in Review

Defilade Capital Management increased its Ascendis Pharma A/S (ASND) stake by 83% in Q2 2026, buying an estimated $10M and bringing the position to 94,843 shares worth $25.3M. The position accounts for 3.39% of the portfolio, ranked #12.

Defilade Capital Management first reported a position in ASND in Q4 2025 and has held it in 3 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Defilade Capital Management held 94,843 shares of Ascendis Pharma A/S worth $25.3M as of Q2 2026.
Defilade Capital Management bought 42,948 Ascendis Pharma A/S shares in Q2 2026, an estimated $10M.
Ascendis Pharma A/S made up 3.39% of Defilade Capital Management's portfolio in Q2 2026, its #12 holding.
Defilade Capital Management first reported a position in Ascendis Pharma A/S in Q4 2025 and has held it in 3 quarters since.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.